Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Inflectra® / Remsima® (CT-P13, biosimilar infliximab) which is the world’s first monoclonal antibody (mAb) biosimilar, received FDA and EMA approval, respectively. Truxima® (CT-P10, biosimilar rituximab) and Herzuma® (CT-P6, biosimilar trastuzumab) also received EMA approval. Celltrion Healthcare’s products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavors to offer high-quality cost-effective solutions through an extensive global network that spans more than 120 different countries.